

Patrick G Kehoe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6004648/publications.pdf>

Version: 2024-02-01

191
papers

17,447
citations

28190

55
h-index

17055

122
g-index

214
all docs

214
docs citations

214
times ranked

19553
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1088-1093.	9.4	2,697
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
3	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	9.4	1,708
4	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
5	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e13950.	1.1	347
6	A full genome scan for late onset Alzheimer's disease. <i>Human Molecular Genetics</i> , 1999, 8, 237-245.	1.4	334
7	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. <i>Nature Genetics</i> , 1999, 21, 71-72.	9.4	260
8	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 280-292.	0.4	246
9	Drug repositioning for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 833-846.	21.5	239
10	A β -Degrading Enzymes: Potential for Treatment of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 944-959.	0.9	228
11	Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. <i>Brain</i> , 2016, 139, 2957-2969.	3.7	220
12	Associations of Anti-Hypertensive Treatments with Alzheimer's Disease, Vascular Dementia, and Other Dementias. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 699-708.	1.2	195
13	Large Meta-Analysis Establishes the ACE Insertion-Deletion Polymorphism as a Marker of Alzheimer's Disease. <i>American Journal of Epidemiology</i> , 2005, 162, 305-317.	1.6	190
14	Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Diseases with Compromise to the Blood Brain Barrier. <i>Chemical Reviews</i> , 2013, 113, 1877-1903.	23.0	187
15	Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. <i>Lancet Neurology</i> , The, 2007, 6, 373-378.	4.9	161
16	Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid- β and tau pathology. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 50.	3.0	159
17	Untargeted Metabolomic Analysis of Human Plasma Indicates Differentially Affected Polyamine and L-Arginine Metabolism in Mild Cognitive Impairment Subjects Converting to Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0119452.	1.1	156
18	Angiotensins in Alzheimer's disease - friend or foe?. <i>Trends in Neurosciences</i> , 2009, 32, 619-628.	4.2	153

#	ARTICLE	IF	CITATIONS
19	Cognitive impact of COVID-19: looking beyond the short term. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 170.	3.0	149
20	The Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2017, 13, 624-633.	0.4	143
21	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
22	Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE to cerebral amyloid angiopathy. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 181-193.	1.8	136
23	Decreased Expression and Activity of Neprilysin in Alzheimer Disease Are Associated With Cerebral Amyloid Angiopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 1012-1021.	0.9	132
24	Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to β -amyloid metabolism. <i>Human Mutation</i> , 2004, 23, 358-367.	1.1	120
25	The cardiovascular and respiratory health of people with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 298-305.	2.2	113
26	Haplotypes extending across ACE are associated with Alzheimer's disease. <i>Human Molecular Genetics</i> , 2003, 12, 859-867.	1.4	108
27	The Coming of Age of the Angiotensin Hypothesis in Alzheimer's Disease: Progress Toward Disease Prevention and Treatment?. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1443-1466.	1.2	105
28	CNS SIRT3 Expression Is Altered by Reactive Oxygen Species and in Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e48225.	1.1	103
29	Endothelin-Converting Enzyme-2 Is Increased in Alzheimer's Disease and Up-Regulated by $A\beta$. <i>American Journal of Pathology</i> , 2009, 175, 262-270.	1.9	102
30	Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. <i>Neurobiology of Aging</i> , 2016, 38, 151-163.	1.5	102
31	Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. <i>Metabolites</i> , 2017, 7, 28.	1.3	102
32	ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2020, 139, 485-502.	3.9	101
33	Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue. <i>American Journal of Neurodegenerative Disease</i> , 2014, 3, 19-32.	0.1	99
34	VEGF-A165b Is an Endogenous Neuroprotective Splice Isoform of Vascular Endothelial Growth Factor A in Vivo and in Vitro. <i>American Journal of Pathology</i> , 2013, 183, 918-929.	1.9	98
35	Neprilysin and Insulin-Degrading Enzyme Levels Are Increased in Alzheimer Disease in Relation to Disease Severity. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 902-914.	0.9	95
36	Endothelin-1 is Elevated in Alzheimer's Disease and Upregulated by Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2012, 29, 853-861.	1.2	95

#	ARTICLE	IF	CITATIONS
37	Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. American Journal of Translational Research (discontinued), 2009, 1, 163-77.	0.0	92
38	Î±-2 macroglobulin gene and Alzheimer disease. Nature Genetics, 1999, 22, 17-19.	9.4	91
39	Distribution and Expression of Picalm in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1071-1077.	0.9	90
40	Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia. Brain, 2014, 137, 1524-1532.	3.7	87
41	Changes with Age in the Activities of Î²-Secretase and the Î³-Degrading Enzymes Nephilysin, Insulin-Degrading Enzyme and Angiotensin-Converting Enzyme. Brain Pathology, 2010, 20, 794-802.	2.1	82
42	Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment. Journal of Alzheimer's Disease, 2010, 20, 17-30.	1.2	78
43	Investigation of antihypertensive class, dementia, and cognitive decline. Neurology, 2020, 94, e267-e281.	1.5	78
44	Sex Differences in the Association of Apolipoprotein E and Angiotensin-Converting Enzyme Gene Polymorphisms With Healthy Aging and Longevity: A Population-Based Study From Southern Italy. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 918-923.	1.7	70
45	Effects of Centrally Acting Angiotensin Converting Enzyme Inhibitors on Functional Decline in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 40, 595-603.	1.2	70
46	APOE Îµ4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome. British Journal of Psychiatry, 2000, 176, 468-472.	1.7	67
47	Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: Different allele frequencies between the North and South of Europe. Experimental Gerontology, 2003, 38, 1015-1020.	1.2	66
48	BIN1 Is Decreased in Sporadic but Not Familial Alzheimer's Disease or in Aging. PLoS ONE, 2013, 8, e78806.	1.1	65
49	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. Alzheimer's Research and Therapy, 2014, 6, 27.	3.0	63
50	The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity. PLoS ONE, 2018, 13, e0206705.	1.1	63
51	The Renin-Angiotensin System and Antihypertensive Drugs in Alzheimer's Disease: Current Standing of the Angiotensin Hypothesis?. Journal of Alzheimer's Disease, 2012, 30, S251-S268.	1.2	62
52	Tumour necrosis factor-Î± gene polymorphisms and Alzheimer's disease. Neuroscience Letters, 2003, 350, 61-65.	1.0	61
53	Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Frontiers in Bioscience - Landmark, 2009, Volume, 4778.	3.0	61
54	Vascular risk and genetics of sporadic late-onset Alzheimer's disease. Journal of Neural Transmission, 2004, 111, 69-89.	1.4	60

#	ARTICLE	IF	CITATIONS
55	Age-Associated Changes of Brain Copper, Iron, and Zinc in Alzheimer's Disease and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1407-1413.	1.2	59
56	Presenilin-1 polymorphism and Alzheimer's disease. <i>Lancet, The</i> , 1996, 347, 1185-1187.	6.3	58
57	Familial influence on variation in age of onset and behavioural phenotype in Alzheimer's disease. <i>British Journal of Psychiatry</i> , 2000, 176, 156-159.	1.7	58
58	Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation. <i>Journal of Neurochemistry</i> , 2012, 123, 997-1009.	2.1	58
59	Oligomeric A β in Alzheimer's Disease: Relationship to Plaque and Tangle Pathology, <i>APOE</i> Genotype and Cerebral Amyloid Angiopathy. <i>Brain Pathology</i> , 2010, 20, 468-480.	2.1	57
60	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.4	56
61	Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2020, 49, 1132-1140.	0.9	55
62	The Role of Variation at A β PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 377-387.	1.2	53
63	Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. <i>Neurobiology of Aging</i> , 2012, 33, 202.e1-202.e13.	1.5	51
64	The dopamine β -hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. <i>BMC Medical Genetics</i> , 2010, 11, 162.	2.1	50
65	No association between the alpha-2 macroglobulin I1000V polymorphism and Alzheimer's disease. <i>Neuroscience Letters</i> , 1999, 262, 137-139.	1.0	48
66	Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, A β , and Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e8764.	1.1	48
67	Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease. <i>RSC Advances</i> , 2012, 2, 5008.	1.7	48
68	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. <i>PLoS ONE</i> , 2017, 12, e0179521.	1.1	48
69	A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. <i>Human Molecular Genetics</i> , 2004, 13, 2647-2657.	1.4	47
70	Sequence variants of IDE are associated with the extent of β -amyloid deposition in the Alzheimer's disease brain. <i>Neurobiology of Aging</i> , 2005, 26, 795-802.	1.5	47
71	Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2009, 6, 22.	3.1	46
72	Current status of renin-angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1229-1242.	1.9	46

#	ARTICLE	IF	CITATIONS
73	Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid- β^2 ($A\beta^2$) Plaque Load and $A\beta^2$ -Synthesizing and $A\beta^2$ -Degrading Enzymes in Frontal Cortex. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1191-1203.	1.2	46
74	Genetic variability at the amyloid- β^2 precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 1999, 269, 67-70.	1.0	43
75	Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE. <i>Neurobiology of Aging</i> , 2007, 28, 1374-1380.	1.5	43
76	Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. <i>Journal of Neuroscience Methods</i> , 2008, 167, 229-236.	1.3	41
77	Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. <i>Brain Research</i> , 2010, 1363, 1-10.	1.1	41
78	Higher Soluble Amyloid β^2 Concentration in Frontal Cortex of Young Adults than in Normal Elderly or Alzheimer's Disease. <i>Brain Pathology</i> , 2010, 20, 787-793.	2.1	41
79	Oxidative Balance in Alzheimer's Disease: Relationship to APOE, Braak Tangle Stage, and the Concentrations of Soluble and Insoluble Amyloid- β^2 . <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1363-1373.	1.2	41
80	Single-Domain Amnesic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 1-19.	0.7	41
81	Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk. <i>PLoS ONE</i> , 2020, 15, e0229541.	1.1	41
82	The <i>SIRT2</i> polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case-control cohorts. <i>Alzheimer's and Dementia</i> , 2013, 9, 392-399.	0.4	40
83	Small RNA modifications in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 145, 105058.	2.1	40
84	Plasminogen and plasmin in Alzheimer's disease. <i>Brain Research</i> , 2010, 1355, 7-15.	1.1	39
85	$A\beta^2$ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 238.	1.7	39
86	Neprilysin Protects against Cerebral Amyloid Angiopathy and $A\beta^2$ -Induced Degeneration of Cerebrovascular Smooth Muscle Cells. <i>Brain Pathology</i> , 2011, 21, 594-605.	2.1	38
87	Activators and inhibitors of the plasminogen system in Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 865-876.	1.6	38
88	Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. <i>European Journal of Epidemiology</i> , 2017, 32, 947-959.	2.5	38
89	Lipid Profiling of Alzheimer's Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism. <i>Cells</i> , 2021, 10, 2591.	1.8	38
90	Review: The renin-angiotensin-aldosterone system and Alzheimer's disease?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 80-93.	1.0	37

#	ARTICLE	IF	CITATIONS
91	Vascular genetic factors and human longevity. <i>Mechanisms of Ageing and Development</i> , 2004, 125, 169-178.	2.2	37
92	APOE promoter, ACE1 and CYP46 polymorphisms and β -amyloid in Alzheimer's disease. <i>NeuroReport</i> , 2004, 15, 95-98.	0.6	37
93	Angiotensin-III is Increased in Alzheimer's Disease in Association with Amyloid- β and Tau Pathology. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 203-214.	1.2	37
94	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017, 21, 1-192.	1.3	37
95	Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease. <i>Human Genetics</i> , 2004, 114, 478-483.	1.8	35
96	Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia. <i>Neurobiology of Aging</i> , 2012, 33, 1345-1355.	1.5	35
97	Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. <i>The Italian Longitudinal Study on Aging. Age</i> , 2013, 35, 441-453.	3.0	35
98	Prion Protein Is Decreased in Alzheimer's Brain and Inversely Correlates with BACE1 Activity, Amyloid- β Levels and Braak Stage. <i>PLoS ONE</i> , 2013, 8, e59554.	1.1	35
99	The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project. <i>European Journal of Human Genetics</i> , 2014, 22, 216-220.	1.4	35
100	Presenilin-1 polymorphism and Alzheimer's disease. <i>Lancet</i> , 1996, 348, 414.	6.3	33
101	MMP-2, -3 and -9 levels and activity are not related to $A\beta$ load in the frontal cortex in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2008, 34, 205-215.	1.8	33
102	Endothelin-converting enzyme-1 in Alzheimer's disease and vascular dementia. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 487-497.	1.8	33
103	A Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 587-597.	1.2	33
104	ACE variants and association with brain $A\beta$ levels in Alzheimer's disease. <i>American Journal of Translational Research (discontinued)</i> , 2010, 3, 73-80.	0.0	32
105	Angiotensins and Alzheimer's disease: a bench to bedside overview. <i>Alzheimer's Research and Therapy</i> , 2009, 1, 3.	3.0	31
106	Calcium Channel Blockers and Alzheimer's Disease: Potential Relevance in Treatment Strategies of Metabolic Syndrome. <i>Journal of Alzheimer's Disease</i> , 2012, 30, S269-S282.	1.2	31
107	Using Alzgene-Like Approaches to Investigate Susceptibility Genes for Vascular Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 145-154.	1.2	31
108	Tools for testing decision-making capacity in dementia. <i>Age and Ageing</i> , 2018, 47, 778-784.	0.7	31

#	ARTICLE	IF	CITATIONS
109	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	4.5	31
110	Accumulation of Insoluble Amyloid- β^2 in Down's Syndrome is Associated with Increased BACE-1 and Nephilysin Activities. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 101-108.	1.2	30
111	Environmental Enrichment Lessens Cognitive Decline in APP23 Mice Without Affecting Brain Sirtuin Expression. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 851-864.	1.2	30
112	Renin Angiotensin Aldosterone System Inhibition in Controlling Dementia-Related Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S575-S586.	1.2	30
113	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 62, 244.e1-244.e8.	1.5	30
114	Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 317-327.	1.8	29
115	Discovery by the Epistasis Project of an epistatic interaction between the <i>GSTM3</i> gene and the <i>HHEX/IDE/KIF11</i> locus in the risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1309.e1-1309.e7.	1.5	29
116	Regional Increase in the Expression of the BCAT Proteins in Alzheimer's Disease Brain: Implications in Glutamate Toxicity. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 891-905.	1.2	28
117	The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin Targeting (RADAR) Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 803-814.	1.2	28
118	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 74.	3.0	28
119	Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. <i>Journal of Neuroscience Methods</i> , 2008, 169, 177-181.	1.3	26
120	Influence of LRP-1 and Apolipoprotein E on Amyloid- β^2 Uptake and Toxicity to Cerebrovascular Smooth Muscle Cells. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 95-110.	1.2	26
121	Associations of Angiotensin Targeting Antihypertensive Drugs with Mortality and Hospitalization in Primary Care Patients with Dementia. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 999-1008.	1.2	26
122	Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2021, 20, 895-906.	4.9	26
123	The Branched-Chain Aminotransferase Proteins: Novel Redox Chaperones for Protein Disulfide Isomerase—Implications in Alzheimer's Disease. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 2497-2513.	2.5	25
124	Clusterin mRNA and Protein in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 337-344.	1.2	24
125	Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer's disease as detected by GC-MS. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 154-65.	0.0	24
126	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. <i>Epigenomics</i> , 2015, 7, 533-537.	1.0	23

#	ARTICLE	IF	CITATIONS
127	Challenges to and Facilitators of Recruitment to an Alzheimer's Disease Clinical Trial: A Qualitative Interview Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1067-1075.	1.2	23
128	Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1537-1553.	1.5	22
129	Antioxidant and Anti-Inflammatory Effects of <i>Scoparia dulcis</i> L. <i>Journal of Medicinal Food</i> , 2011, 14, 1576-1582.	0.8	22
130	A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 981-989.	1.2	22
131	Angiotensin II-inhibiting drugs have no effect on intraneuronal A β or oligomeric A β levels in a triple transgenic mouse model of Alzheimer's disease. <i>American Journal of Translational Research (discontinued)</i> , 2011, 3, 197-208.	0.0	22
132	Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical Trial. <i>Journal of Orthopaedic and Sports Physical Therapy</i> , 2016, 46, 714-725.	1.7	21
133	Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. <i>Neurobiology of Aging</i> , 2017, 49, 215.e1-215.e8.	1.5	21
134	Ethical aspects of research into Alzheimer disease. A European Delphi Study focused on genetic and non-genetic research. <i>Journal of Medical Ethics</i> , 2009, 35, 140-144.	1.0	20
135	Interaction of insulin and PPAR- γ genes in Alzheimer's disease: the Epistasis Project. <i>Journal of Neural Transmission</i> , 2012, 119, 473-479.	1.4	20
136	TNFR-associated factor-2 (TRAF-2) in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1052-1060.	1.5	18
137	Regional Differences in Effects of APOE- ϵ 4 on Cognitive Impairment in Non-Demented Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 135-142.	0.7	18
138	LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: Relationship to cerebral amyloid angiopathy and APOE status. <i>Neuroscience Letters</i> , 2012, 525, 123-128.	1.0	18
139	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 153-162.	1.2	18
140	Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 815-824.	1.2	18
141	Altered Expression of Human Mitochondrial Branched Chain Aminotransferase in Dementia with Lewy Bodies and Vascular Dementia. <i>Neurochemical Research</i> , 2017, 42, 306-319.	1.6	17
142	Evidence That Parietal Lobe Fatty Acids May Be More Profoundly Affected in Moderate Alzheimer's Disease (AD) Pathology Than in Severe AD Pathology. <i>Metabolites</i> , 2018, 8, 69.	1.3	17
143	Tumour necrosis factor- α (TNF- α) and miRNA expression in frontal and temporal neocortex in Alzheimer's disease and the effect of TNF- α on miRNA expression in vitro. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 156-62.	0.4	17
144	Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , 2012, 1, 266-79.	0.1	17

#	ARTICLE	IF	CITATIONS
145	Quantitative Measurement of [Na ⁺] and [K ⁺] in Postmortem Human Brain Tissue Indicates Disturbances in Subjects with Alzheimer's Disease and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 851-857.	1.2	16
146	Investigation of τ phosphorylated at serine 8 ($p\tau^{S8}$) in Alzheimer's disease, dementia with Lewy bodies and vascular dementia. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 428-444.	1.8	16
147	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 525-535.	1.2	16
148	Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimer's Disease Pathology (ASCEND) Study. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 109-117.	1.2	15
149	Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer's disease. <i>Neuroscience Letters</i> , 2006, 408, 141-145.	1.0	14
150	Comparison of Antihypertensive Drug Classes for Dementia Prevention. <i>Epidemiology</i> , 2020, 31, 852-859.	1.2	14
151	Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse. <i>American Journal of Translational Research (discontinued)</i> , 2012, 4, 151-64.	0.0	14
152	Protein and gene expression of tumour necrosis factor receptors I and II and their promoter gene polymorphisms in Alzheimer's disease. <i>Experimental Gerontology</i> , 2007, 42, 538-544.	1.2	13
153	Genetic variation in MME in relation to neprilysin protein and enzyme activity, $A\beta$ levels, and Alzheimer's disease risk. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2012, 3, 30-8.	0.4	13
154	Is Amyloid- β an Innocent Bystander and Marker in Alzheimer's Disease? Is the Liability of Multivalent Cation Homeostasis and its Influence on Amyloid- β Function the Real Mechanism?. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 69-85.	1.2	12
155	Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1518-1520.	1.5	11
156	The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1535-1547.	1.2	11
157	BCAT-induced autophagy regulates $A\beta$ load through an interdependence of redox state and PKC phosphorylation-implications in Alzheimer's disease. <i>Free Radical Biology and Medicine</i> , 2020, 152, 755-766.	1.3	11
158	Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink. <i>BMJ Open</i> , 2016, 6, e012044.	0.8	10
159	Elevated cerebrospinal fluid sodium in hypertensive human subjects with a family history of Alzheimer's disease. <i>Physiological Genomics</i> , 2020, 52, 133-142.	1.0	10
160	Dysregulation of ACE-1 in Normal Aging and the Early Stages of Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 1775-1783.	1.7	10
161	Evidence that the gene encoding insulin degrading enzyme influences human lifespan. <i>Human Molecular Genetics</i> , 2008, 17, 2370-2378.	1.4	9
162	Cerebral $A\beta_{240}$ and systemic hypertension. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1993-2005.	2.4	9

#	ARTICLE	IF	CITATIONS
163	What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 51.	3.0	8
164	Zibotentan, an Endothelin A Receptor Antagonist, Prevents Amyloid- β^2 -Induced Hypertension and Maintains Cerebral Perfusion. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1185-1199.	1.2	8
165	LRP-1 variation is not associated with risk of Alzheimer's disease. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010, 1, 104-13.	0.4	8
166	The Association Between APOE ϵ^4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 241-246.	1.2	7
167	Effect of Visit-to-Visit Blood Pressure Variability on Cognitive and Functional Decline in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1499-1510.	1.2	7
168	An exploration of the potential mechanisms and translational potential of five medicinal plants for applications in Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , 2013, 2, 70-88.	0.1	7
169	Differences in allele frequencies of ACE I/D polymorphism between Northern and Southern Europe at different ages. <i>Atherosclerosis</i> , 2007, 193, 455-457.	0.4	6
170	Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients. <i>Age</i> , 2011, 33, 409-419.	3.0	6
171	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment of subcortical ischaemic vascular dementia (AFFECT): study protocol. <i>Trials</i> , 2016, 17, 324.	0.7	6
172	Divergence in the activity of the N- and C- catalytic domains of ACE1 - implications for the role of the renin-angiotensin system in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 57.	2.4	5
173	Evidence that the Kennedy and polyamine pathways are dysregulated in human brain in cases of dementia with Lewy bodies. <i>Brain Research</i> , 2020, 1743, 146897.	1.1	5
174	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 22.	3.0	5
175	UK consensus on pre-clinical vascular cognitive impairment functional outcomes assessment: Questionnaire and workshop proceedings. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1402-1414.	2.4	4
176	Commentary (The Renin Angiotensin System in Alzheimers Disease - Do Updates Highlight a Clinical and) <i>Tj ETQq0.0.0 rgBT /Overlock 1</i>	0.7	3
177	Losartan to slow the progression of mild-to-moderate Alzheimer's disease through angiotensin targeting: the RADAR RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-72.	0.9	3
178	The influence of tumour necrosis factor- β (TNF- β) on amyloid- β^2 (A β^2)-degrading enzymes in vitro. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 409-15.	0.4	3
179	Blood type gene locus has no influence on ACE association with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1767.e1-1767.e2.	1.5	2
180	Reply: Atherosclerosis and vascular cognitive impairment neuropathological guideline. <i>Brain</i> , 2017, 140, e13-e13.	3.7	2

#	ARTICLE	IF	CITATIONS
181	Renin Angiotensin System as a Potential Treatment Target for Traumatic Brain Injury: A Systematic Review and Meta-Analysis. <i>Journal of Neurotrauma</i> , 2022, 39, 473-486.	1.7	2
182	Molecular Determinants of Human Longevity. <i>Advances in Clinical Chemistry</i> , 2005, 39, 185-210.	1.8	1
183	OS-06-05: EXPLORING ACE2 AS A NOVEL THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1659.	0.4	1
184	Angiotensin receptor blockers associated with decreased incidence and progression of dementia in older men with cardiovascular disease. <i>Evidence-Based Mental Health</i> , 2010, 13, 75-75.	2.2	0
185	Use of angiotensin-converting enzyme inhibitors for Alzheimer's disease: an update. <i>Neurodegenerative Disease Management</i> , 2013, 3, 511-514.	1.2	0
186	Aluminium in the Diet, Cognitive Decline and Dementia. , 2011, , 2829-2850.		0
187	Alcohol Consumption in Predementia and Dementia Syndromes. , 2011, , 3011-3044.		0
188	Title is missing!. , 2020, 15, e0229541.		0
189	Title is missing!. , 2020, 15, e0229541.		0
190	Title is missing!. , 2020, 15, e0229541.		0
191	Title is missing!. , 2020, 15, e0229541.		0